诺华肾病治疗创新药诺锐达 （盐酸阿曲生坦片）在京东健康全网首发

Core Insights - Novartis has launched its innovative drug, Noreda (Acrylamide Hydrochloride Tablets), on JD Health, marking it as the first approved non-immunological therapy for adult patients with primary IgA nephropathy in China [1][2] - The drug is a highly selective endothelin A (ETA) receptor antagonist, filling a significant gap in non-hormonal basic treatments for this condition [2] Group 1 - Noreda is designed to reduce the risk of rapid disease progression in IgA nephropathy patients, which is prevalent among young adults aged 20 to 30 in China [1] - Clinical studies indicate that approximately 50% of IgA nephropathy patients with persistent proteinuria may progress to renal failure within 10 to 20 years if not effectively managed [1] - The collaboration between JD Health and Novartis aims to enhance the accessibility and precision of innovative treatments for patients nationwide [1][2] Group 2 - JD Health plans to deepen its focus on chronic disease management, particularly in kidney diseases, by leveraging its robust healthcare service ecosystem [2] - The introduction of Noreda is expected to provide new options for long-term disease management alongside existing standard treatments [2] - JD Health aims to offer comprehensive digital health management solutions for patients, improving the quality of life for those with kidney diseases and other chronic conditions [2]